DexCom Inc (DXCM)vsEstablishment Labs Holdings Inc (ESTA)
DXCM
DexCom Inc
$78.62
+0.08%
HEALTHCARE · Cap: $32.47B
ESTA
Establishment Labs Holdings Inc
$68.97
+3.02%
HEALTHCARE · Cap: $1.76B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 1921% more annual revenue ($4.97B vs $245.82M). DXCM leads profitability with a 20.1% profit margin vs -15.8%. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
ESTA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.9%
Fair Value
$676.00
Current Price
$78.62
$597.38 discount
Margin of Safety
-12.6%
Fair Value
$64.57
Current Price
$68.97
$4.40 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Revenue surging 31.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 94.5x book value
ROE of -295.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : ESTA
The strongest argument for ESTA centers on Revenue Growth. Revenue growth of 31.7% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : ESTA
The primary concerns for ESTA are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 12.20 is elevated, increasing financial risk.
Key Dynamics to Monitor
DXCM profiles as a mature stock while ESTA is a hypergrowth play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.48 — expect wider price swings.
ESTA is growing revenue faster at 31.7% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 31/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Establishment Labs Holdings Inc
HEALTHCARE · MEDICAL DEVICES · USA
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for cosmetic and reconstructive plastic surgery. The company is headquartered in Alajuela, Costa Rica.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?